Hospital Acquired Infection

Magnolia Medical Technologies publishes survey report on hospitalization risks

By LabPulse.com staff writers

The greatest concern about hospitalization among the 1,002 adults in the U.S. surveyed was the high cost, which outpaced concerns about antimicrobial-resistant bacterial infections, sepsis, hospital-acquired infections, and other risks.

July 26, 2023

Researchers find that prompt C. difficile testing could reduce hospital infection spread, morbidity

By Elissa Wolfson

Hospital policies allowing nurses to independently initiate testing for the bacterium C. difficile could reduce infection spread and associated morbidity.

May 11, 2023

Antibiotic susceptibility test in study reveals current antibiotics may cure superbugs

By Elissa Wolfson

The test revealed that some of the commercial, FDA-approved antibiotics can treat drug-resistant superbug infections.

May 1, 2023

Researchers find hidden bacteria that pose antimicrobial resistance risk to hospital patients

By Elissa Wolfson

Researchers have found that carriers of specific hidden bacteria have a 14% chance of developing an antibiotic-resistant infection within 30 days of hospitalization.

January 31, 2023

Sentinel creates coronavirus test, adds more PCR tests

By LabPulse.com staff writers

The company's Stat-NAT COVID-19 assay is a freeze-dried, ready-to-use, real-time polymerase chain reaction (PCR) mix that can detect the presence of the SARS-CoV-2 virus, which causes COVID-19, in human respiratory tract specimens in about 90 minutes.

March 12, 2020

NeuMoDx and Sentinel partner on PCR assays

By LabPulse.com staff writers

New molecular diagnostics will be developed in a range of areas, including for use in post-transplant infections, parasitic and hospital-acquired infections, and respiratory infections. The collaborative work will incorporate Sentinel's Stat-NAT technology, which the companies said was designed to stabilize the activity of the PCR mix to boost shelf life, among other advantages.

December 9, 2019

GNA Biosolutions secures $13.5M in new funding round

By LabPulse.com staff writers

GNA said it plans to use the funds to advance the development of its point-of-care molecular diagnostic platform as well as help bring it to the clinic -- first in the European Union and then in the U.S. market. The platform can support the creation of simple, cost-effective molecular diagnostic tests and has already facilitated the production of more than 30 internal assays for hospital-acquired infections and tuberculosis, among other diseases, according to the firm.

August 4, 2019

Page 1 of 1